Navigation Links
Freedom Meditech to Provide Live Demonstration of ClearPath DS-120 Eye Scan at the 13th Annual Diabetes Technology Meeting
Date:10/30/2013

SAN DIEGO, Oct. 30, 2013 /PRNewswire/ -- Freedom Meditech, Inc. has announced that the company has been invited to present a live demonstration of the ClearPath DS-120™ at the 13th Annual Diabetes Technology Meeting, the premier event in the United States for showcasing latest technological advances for people with diabetes. Cleared by the U.S. Food and Drug Administration (FDA) in January 2013, the ClearPath DS-120 is a first-in-class, non-invasive tool designed to quickly and accurately measure autofluorescence through a six second scan of the crystalline lens of the eye. A significant number of independent peer-reviewed studies have suggested that elevated lens autofluorescence may be an early indicator of the presence of diabetes.

"The Diabetes Technology Meeting provides an opportunity to educate diabetes professionals about the clinical value of non-invasive lens autofluorescence and the associated market size estimated at $4 billion worldwide," said Craig Misrach, CEO of Freedom Meditech. "ClearPath can facilitate the co-management of patients between physicians and eye care professionals, which in turn, can maximize earlier detection and monitoring of patients at risk of developing complications related to diabetes."

The meeting will feature more than 500 clinicians and scientists from 24 countries and will focus on applying science and technology to prevent and treat diabetes. The goal of the meeting is to facilitate the creation of new and cost-effective tools between diabetes thought leaders and developers.

"The most cutting-edge inventions in the global diabetes marketplace are featured at the Diabetes Technology Meeting and it's only appropriate that non-invasive lens autofluorescence be included," said David C. Klonoff, M.D., F.A.C.P., chair of the Diabetes Technology Meeting. "Technologies that enable the early detection of diabetes with a footprint capable of reaching a wider patient population are essential to disease intervention and reversing the direction of the Type 2 diabetes epidemic."

Freedom Meditech will conduct a live demonstration of the ClearPath at 2:10 p.m. on November 2, 2013 at the Diabetes Technology Meeting taking place at the Hyatt Regency San Francisco Airport in Burlingame, California.

About ClearPath DS-120™

The ClearPath DS-120™ Lens Fluorescence Biomicroscope is cleared by FDA as a tool for the measurement of autofluorescence by scanning the crystalline lens of the eye with a blue light. In independent scientific studies published in peer-reviewed journals, elevated autofluorescence measurements have been linked to high levels of advanced glycosylated end products which accumulate as a result of the aging process and the presence of systemic disease.

The ClearPath scan is pain free, takes just six seconds and produces an immediate, quantitative result available to the patent and healthcare provider. Unlike some eye exams, the scan does not require dilation. The ClearPath is completely non-invasive and does not require a blood draw to produce a result. The device has a small footprint, sits on a table top, and employs an easy to use touch screen display that can be wirelessly linked to a practitioner's electronic medical record system.

About Freedom Meditech

Freedom Meditech, Inc. is a medical device company focused on the commercialization of novel ophthalmic technologies for the detection of disease and management of patient health. The company has received FDA clearance for its first product, ClearPath DS-120™, a non-invasive tool for the measurement of autofluorescence in the eye. I-SugarX is the company's second product currently in development as a non-invasive ophthalmic glucose monitor that measures glucose levels in the eye for people with diabetes. The company maintains corporate and engineering operations in San Diego, CA with supporting research and development activities throughout the state of Ohio. For more information, visit www.freedom-meditech.com or find us on TwitterFacebook and LinkedIn.


'/>"/>
SOURCE Freedom Meditech
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
2. Freedom Innovations Wins the American Technology Award for Health & Medical Technologies
3. FreedomPACS, Radiology PACS and Cloud Image Storage Provider, Releases Results of County Hospital Case Study, Revealing Savings of 75 Percent
4. Updated HHS Mandate Continues Attack on Religious Freedom
5. AUL Files Seventh Brief Supporting First Amendment Freedom of Conscience
6. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
7. OralHygenix Announces Freedom Oral Care System (FOCS) for People with Physical and Mental Disabilities
8. Golden Meditech Holdings Limited Announces 2011/ 2012 Annual Results
9. Golden Meditech Holdings Limited Announces Updates on Medical Devices Subsidiary Latest Development
10. Golden Meditech Announces 2012 / 2013 Interim Results
11. Zynx Health Launches Unrivaled MEDITECH Integration for Evidence-based Care Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Australien, 24. Februar 2017 ITL Limited, ... des Gesundheitsbereiches, ist erfreut, für das zum 31. ... entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine ... zum Wachstum" finden Sie hier . ... nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... , Feb. 23, 2017 ... insights on the various drugs being developed ... covers all the drugs that are in ... Clinical). The pipeline focuses on novel pharmacologic ... antibodies, stem cell therapies, recombinant proteins and ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of ... of Pittsburgh points to eight genes that may explain why susceptibility to one of ... results of a study published today in the journal npj Schizophrenia. , “There ...
(Date:2/24/2017)... ... ... The Smart Machine Age is here, and it’s disrupting everything. Not only could ... in the United States may be taken over by technology in the next five ... steamrolls over colleagues is drawing to a close. Success will belong to those who ...
(Date:2/24/2017)... ... 24, 2017 , ... With millions of Americans and people ... we all are aware of our options and are empowered with strength and ... launch of its newest edition of "Vision and Hearing" in USA Today, that ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal ... Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, ... his attempts to overcome them. , Schanssema, initially unsure of the career path he ...
(Date:2/24/2017)... ... 2017 , ... The California State University Institute for Palliative Care ... interested in palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing ... Diego on Sept. 28 and 29, 2017, on the campus of California State University ...
Breaking Medicine News(10 mins):